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Abstract: Background and Objectives: Dyslipidaemia and its associated complications have been
reported to increase mortality among type 2 diabetes mellitus (T2DM) patients. However, there is a
dearth of data on the incidence of dyslipidemia among Ghanaian patients with T2DM. This study
evaluated dyslipidemia among newly diagnosed T2DM patients at Dormaa Presbyterian Hospital,
Ghana. Materials and Methods: This cross-sectional study recruited a total of 215 participants at the
Presbyterian Hospital, Dormaa-Ghana. A well-structured questionnaire was administered to collect
demographic data. Predisposing factors of dyslipidemia such as BMI, hypertension, and family
history of diabetes were also obtained. Lipid profile was performed on the serum obtained from
each respondent. Dyslipidaemia was defined as total cholesterol (TC) >200 mg/dL, triglyceride (TG)
>150 mg/dL, low density lipoprotein cholesterol (LDL-c) >100 mg/dL, and high-density lipoprotein
cholesterol (HDL-c) <40 in males and <50 mg/dL in females. Combinations of the individual
parameters of dyslipidaemia were further evaluated. Results: Of the total (215) participants, 86 (40%)
were males and 129 (60%) were females, representing a ratio of 1:1.5. High total cholesterol was more
prevalent in females (69.0%) than males (53.5%). Generally, dyslipidaemia was predominant among
those aged >40 years, with the exception of increased LDL-c (25.1%), which was higher among the
20–40 years age group. The male participants exhibited significantly (p < 0.001) higher percentages of
all combined measures of dyslipidaemia—such as high TG and reduced HDL-c (77.9%), high TG and
elevated LDL-c (75.6%) and high LDL and low HDL (65.1%). BMI was significantly associated with
HDL levels (p = 0.02), whereas family history of diabetes was associated with TC (p = 0.004) and TG
levels (p = 0.019). Conclusion: Combined dyslipidaemia is relatively high among newly diagnosed
T2DM patients in Ghana, and in those >40 years. Gender is significantly associated with combined
dyslipidaemia in T2DM, and males may be at a higher risk than females. BMI and family history of
diabetes are potential risk factors of dyslipidaemia in T2DM.
Keywords: diabetes; combined dyslipidemia; gender; family history; BMI
1. Introduction
The International Diabetes Federation IDF [1] indicated that, globally, 415 million people lived
with diabetes mellitus (DM) in 2015 and approximately two out of 20 subjects affected by diabetes
lived in low and middle income countries [1]. Currently, studies have shown that in Africa, about
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14.2 million adults have diabetes, with a prevalence of 3.2% [2]. Furthermore, in Ghana, about 266,200
of the population within the age range of 20–79 years are suffering from DM, representing a prevalence
rate of 1.9% [1]. In Sub-Saharan Africa, it is estimated that 30% of patients admitted in cardiovascular
intensive care units have diabetes mellitus, and subsequent cardiovascular disease is responsible for
mortality in two out of three diabetes patients [3].
Type 2 diabetes mellitus (T2DM) occurs when insulin production is defective or its action on
the metabolism of body sugars is defective [4]. Dyslipidaemia and atherogenic dyslipidaemia cause
complications and mortality in type 2 diabetes patients, in addition to being strong potential risk
factors for predicting cardiovascular diseases [5,6]. Samdani et al. [7] defined dyslipidaemia as the
presence of one or more disorders in serum lipids in an individual [7].
Dyslipidaemia is a metabolic disturbance whichstimulates insulin resistance in adipose and
muscle tissues [8]. Insulin resistance then results in persistent hyperglycaemia, in which the body
becomes susceptible to protein glycation and formation of sorbitol, advanced glycated end products,
and free radicals [8]. Thus, in type 2 diabetes, there is the likelihood of alterations in lipids and
lipoprotein parameters, which contribute to oxidative stress [9]. The formation of these free radicals
and advanced glycated end products, and subsequent oxidative stress causes damage to endothelial
tissues [10]. The dysfunction of endothelial tissue can stimulate atherosclerotic events on blood vessels,
which can progress to cardiovascular diseases [9].
Dyslipidaemia becomes atherogenic when there is combined elevation of triglycerides (TG) and
small compressed low density lipoprotein cholesterol (LDL-c), and decreased high density lipoprotein
cholesterol (HDL-c) in the blood [11]. While dyslipidaemia is a devastating complication of Type 2
diabetes, different populations may exhibit erratic changes in their lipid profiles [12] For instance,
LDL-cis somewhat elevated among non-Africans and lowered in other racial groups of diabetes
mellitus [12].
In urban Ghana, at least 6% of adults are affected by type 2 DM [13]. Even though research
elsewhere has shown the prevalence of dyslipidaemia and high predisposition risk of atherosclerotic
vascular diseases among type 2 diabetes patients [14,15], very little has been done and reported among
Ghanaian diabetes patients, and the degree to which these observations are true in the Ghanaian
context is unknown.
There is, therefore, the need for a better insight into dyslipidemia among type 2 DM patients
in Ghana, in order to unravel scientific statistics required for understanding the occupancy of this
complication. It is against this background that the present study was conducted to evaluate
dyslipidaemia among newly diagnosed type 2 diabetes outpatients in Ghana.
2. Materials and Methods
2.1. Study Design and Setting
This descriptive cross-sectional study was conducted at the Dormaa Presbyterian Hospital of the
Dormaa Central Municipality of the Brong-Ahafo Region of Ghana. Dormaa Municipality with its
administrative capital at Dormaa-Ahenkro is one of the twenty-seven Districts and Municipalities in
the Brong-Ahafo Region of Ghana. The biggest health facility in Dormaa Municipality is the Dormaa
Presbyterian Hospital (DPH), which provides services for both acute and chronic disease conditions as
well as receive referrals from other neighboring districts, regions and nearest town in La Cote D’ Ivoire.
2.2. Study Participants and Sampling Technique
Purposive sampling was used to recruit only newly diagnosed male and female T2DM patients
(target population) at the Dormaa Presbyterian Hospital from the diabetic clinic, after which, simple
random sampling was used to obtain a total sample size of 215. Newly diagnosed T2DM patients
≥18 years who were not on any cardiovascular therapy (such as statin or other lipid-lowering therapy)
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were included in the study. Pregnant women, patients with diagnosed diabetes for more than 1 year,
and diabetes patients with renal disorders and other complications were all excluded from the study.
2.3. Ethical Considerations
Ethical approval was granted by the Dormaa Central Municipal Health Directorate and the
Authorities of the Presbyterian Hospital, DCMHD/EC/013/18, from 12 April 2018. The study was
conducted in accordance with the Helsinki Declaration and its later amendments or comparable ethical
standards [16]. A written informed consent form was provided to each participant to willingly decide
to be part of the study after the aim of the study and the guarantee of anonymity were discussed
with them.
2.4. Questionnaire Administration
A well-structured questionnaire was used to collect demographic data such as age, gender,
occupational status, and educational level. Data on predisposing factors such as hypertension, BMI,
and medical history of the study participants were also obtained from their medical folders and
hospital database.
2.5. Sample Collection and Biochemical Analysis
Two milliliters (2mL) of venous blood was taken from each participant after an overnight fast for
at least 12 h, via phlebotomy into serum separator tubes. Blood was allowed to clot for at least 15–25
min, after which, serum was obtained by centrifugation at 3000 rpm for 5 min. Lipid profile analysis
was performed on the serum obtained from each participant to evaluate total cholesterol (TC), high
density lipoprotein cholesterol (HDL-c), and triglycerides (TG), by spectrum photometric methods,
using the MINDRAY® 130 Chemistry Analyser. Low-density lipoprotein cholesterol (LDL-c) was
calculated using the Friedewald formula [17]:
[LDL Chol] = [Tot Chol] − [HDL Chol] − [TG]/2.2(1) mmol/L.
Dyslipidemia was defined according to the American Diabetes Association criteria: High total
cholesterol (TC) >200 mg/dL, high triglyceride (TG) >150 mg/dL, elevated low density lipoprotein
cholesterol (LDL-c) >100 mg/dL, and decreased high density lipoprotein cholesterol (HDL-c) <40 in
males and <50 mg/dL in females [18].
Blood pressure (BP) was measured by professional nurses in the upper right arm of each participant
using automated sphygmomanometers, after 10 min of rest in a sitting position. BP was measured
twice and the average value was recorded. Blood pressure was defined using the American College of
Cardiology (ACC)/American Heart Association (AHA) guidelines: normal (<120/<80 mmHg), elevated
(120–129/<80 mmHg), prehypertension (≥130/80 mmHg), and hypertension (≥140/80 mmHg) [19].
2.6. Statistical Analyses
Data were entered into Microsoft Excel 2013, and the Statistical Package for Social Science (SPSS)
version 23.0 and GraphPad prism 7.0 were used to process the data. Data were represented as mean ±
standard deviation (SD). The Chi-square test was used to analyze categorized variables. A p-value
<0.05 was considered statistically significant for all analyses.
3. Results
Of the total of 215 participants, 86 (40%) were males and 129 (60%) were females, representing a
ratio of 1:1.5. The majority of the respondents (53.9%) were ≥41 years and were married (63.7%). With
regards to religious affiliation, Christians recorded the highest percentage (51.2%) followed by Muslims
(45.1%), and Traditionalists (3.7%). Most of the respondents (60%) acquired basic education while a few
attained higher education (14%). A higher percentage (32.6%) of the participants were self-employed,
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with a few (21.4%) into farming. Mean HDL-c and BMI were 32. 9 mg/dL and 26.7 kg/m2 respectively
Table 1.
Table 1. Baseline characteristics of study participants.
Characteristics Frequency (n = 215) Percentage (%)
Sex
Male 86 40.0%
Female 129 60.0%
Age (years)
20–40 99 46.1%
41–59 59 27.4%
≥60 57 26.5%
Marital Status
Married 137 63.7%
Widowed 27 12.6%
Single 51 23.7%
Religious Status
Christianity 110 51.2%
Islamic 97 45.1%
Traditional believer 8 3.7%
Educational Status
Basic 129 60.0%
SHS/′O′ level/′A′ level 56 26.0%
Tertiary 30 14.0%
Occupational Status
Public/Private employment 51 23.7%
Unemployed 48 22.3%
Self-employment 70 32.6%
Farming 46 21.4%
BMI (26.7 ± 5.1 kg/m2)
TC (231 ± 43.7 mg/dL)
TG (147 ± 31.8 mg/dL)
HDL-c (32. 9 ± 11.8 mg/dL)
LDL-c (97.8 ± 17.3 mg/dL)
Systolic BP (141 ± 29.6 mmHg)
Diastolic BP (94 ± 19.4 mmHg)
Results are presented as mean (± SD) where appropriate. BP—Blood Pressure, BMI—Body Mass Index,
TC—Total Cholesterol, TG—Triglyceride, LDL-c—Low Density Lipoprotein Cholesterol, HDL-c—High Density
Lipoprotein Cholesterol.
Table 2 shows the prevalence of dyslipidaemia stratified by gender and age. The results show
that high TC was more prevalent (69.0%) in females than in males (53.5%). Males with elevated
triglyceride were 40 (46.5%), 59.3% were identified with increased LDL-c, and 62.8% exhibited lower
HDL-c (<40 mg/dL). Elevated TG (>150 mg/dL), high LDL-c (>100 mg/dL), and decreased HDL-c
(<50 mg/dL) were recorded as 49.6%, 39.5%, and 69.0%, respectively, among the female participants.
Generally, dyslipidaemia was more prevalent in those aged >40 years than in those <40 years, with the
exception of increased LDL-c (25.1%), which was higher among the 20–40 years age group. There was
no significant association between dyslipidaemia, age, and gender (p > 0.05 each).
Table 3 shows that combined dyslipidaemia of high TG and reduced HDL-c was predominant
in males (77.9%), and most (37.6%) of them were >40 years. In addition, the male participants
recorded a higher percentage (75.6%) for combined dyslipidaemia of high TG and elevated LDL-c
levels (TG ≥150 mg/dL and LDL-c >100 mg/dL), with majority (40%) of these men being >40 years.
Moreover, combined dyslipidaemia of high LDL-c and low HDL-c was also predominant in the male
participants (65.1%) and in those aged above 40 years (34.9%). The female participants generally
recorded lower percentages of the various combinations of dyslipidaemia as compared to their male
counterparts. There was a significant association between gender and all combined dyslipidaemia.
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Table 2. Prevalence of individual parameters of dyslipidaemia and their association with gender
and age.
Characteristic TC TG LDL-c HDL-c
High Low High Low High Low Low High
Total 135 (62.8) 80 (37.2) 104 (48.4) 111 (51.6) 102 (47.4) 113 (52.6) 143 (66.5) 72 (33.5)
Gender
Male 46 (53.5%) 40 (46.5%) 40 (46.5%) 46 (53.5%) 51 (59.3%) 35 (40.7%) 54 (62.8%) 32 (37.2%)
Female 89 (69.0%) 40 (31.0%) 64 (49.6%) 65 (50.4%) 51 (39.5%) 78 (60.5%) 89 (69.0%) 40 (31.0%)
p-value 0.157 0.784 0.082 0.542
Age (years)
20–40 54 (25.1%) 45 (21.0%) 43 (20.0%) 56 (26.1%) 54 (25.1%) 45 (21.0%) 70 (32.6%) 29 (13.5%)
41–59 48 (22.3%) 11 (5.1%) 40 (18.6%) 19 (8.8%) 29 (13.5%) 30 (13.9%) 40 (18.6%) 19 (8.8%)
≥60 33 (15.3%) 24 (11.2%) 22 (10.2%) 35 (16.3%) 19 (8.8%) 38 (17.7%) 31 (14.4%) 26 (12.1%)
p-Value 0.087 0.094 0.304 0.681
TC—Total Cholesterol, TG— Triglyceride, LDL-c—Low Density Lipoprotein Cholesterol, HDL-c—High Density
Lipoprotein Cholesterol.
Table 3. Prevalence of combined dyslipidaemia and its association with age and gender.
Characteristic Combined Dyslipidaemia
High TG and
Low HDL-c
Low TG and
High HDL-c
High TG and
High LDL-c
Low TG and
Low LDL-c
High LDL-c
and Low
HDL-c
Low LDL-c
and High
HDL-c
Total 156 (72.6%) 59 (27.4%) 148 (68.8%) 67 (31.2%) 137 (63.7%) 78 (36.3%)
Gender
Male 67 (77.9%) 19 (22.1%) 65 (75.6%) 21 (24.4%) 56 (65.1%) 30 (34.9%)
Female 89 (69.0%) 40 (31.0%) 83 (64.3%) 46 (35.7%) 81 (62.8%) 48 (37.2%)
p-Value <0.001 <0.001 <0.001
Age (years)
20-40 75 (34.9%) 24 (11.2%) 62 (28.9%) 37 (17.2%) 62 (28.9%) 37 (17.2%)
41–59 42 (19.5%) 17 (7.9%) 46 (21.4%) 13 (6.0%) 40 (18.6%) 19 (8.8%)
≥60 39 (18.1%) 18 (8.4%) 40 (18.6%) 17 (7.9%) 35 (16.3%) 22 (10.2%)
p-Value 0.970 0.797 0.624
TC—Total Cholesterol, TG—Triglyceride, LDL-c—Low Density Lipoprotein Cholesterol, HDL-c—High Density
Lipoprotein Cholesterol.
From the study, 6.5% were underweight (BMI <18.5 kg/m2), and those with normal weight were
31.2% (BMI = 18.5–24.9 kg/m2). Out of the 215 respondents, 36.8% of the participants were found to be
overweight, while 23.7% were obese. With regards to blood pressure, 26.0% of the participants had
normal BP, while 30.3% were pre-hypertensive. The majority of the participants were hypertensive
(43.7%), and more than half (80%) had family a history of diabetes (Figure 1).
The results in Table 4 show that 25.1% of the respondents were hypertensive with high TC,
20.0% were hypertensive with high TG, 29.3% were hypertensive with low HDL-c, and those having
hypertension with increased LDL-c levels were 18.6%. Results from the Table 4 indicated that 14.9% of
the respondents were obese, and at the same time exhibited high TC levels. The majority (43.7%) of
the respondents who had family history of diabetes, also recorded significantly high TC (p = 0.004).
In addition, 34.0% of the participants were identified with family history of diabetes and high TG
levels, and a little above half (52.5%) had family history of diabetes and low HDL-c levels. There was a
significant association between respondents with family history of diabetes and high TG (p = 0.019).
Furthermore, a significant association was observed between BMI and low HDL-c levels (p = 0.020) at
95% confidence interval.
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Table 4. Predisposing factors associated with dyslipidaemia and test of association between predisposing factors and individual parameters of dyslipidaemia.
Factors TC p-Value TG p-Value HDL-c P-value LDL-c p-Value
>200 mg/dL <200 mg/dL >150 mg/dL <150 mg/dL <40 mg/dL >40 mg/dL >100 mg/dL <100 mg/dL
Measured BP
Normal 30 (14.0%) 27 (12.6%)
0.092
27 (12.6%) 30 (14.0%)
0.284
40 (18.6%) 16 (7.5%)
0.67
24 (11.1%) 32 (14.9%)
0.146Pre-HTN 51 (23.7%) 13 (6.0%) 34 (15.8%) 30 (14.0%) 40 (18.6%) 24 (11.1%) 38 (17.7%) 27 (12.6%)
HTN 54 (25.1%) 40 (18.6%) 43 (20.0%) 51 (23.6%) 63 (29.3%) 32 (14.9%) 40 (18.6%) 54 (25.1%)
BMI (kg/m2)
Underweight 8 (3.7%) 5 (2.3%)
0.996
5 (2.3%) 8 (3.7%)
0.812
11 (5.1%) 2 (0.9%)
0.02
3 (1.4%) 10 (4.7%)
0.419
Normal 43 (20.0%) 24 (11.2%) 32 (14.9%) 35 (16.3%) 17 (7.9%) 50 (23.3%) 37 (17.1%) 30 (14.0%)
Overweight 52 (24.2%) 31 (14.4%) 37 (17.2%) 46 (21.4%) 68 (31.6%) 15 (7.0%) 35 (16.3%) 48 (22.3%)
Obese 32 (14.9%) 20 (9.3%) 31 (14.4%) 21 (9.7%) 47 (21.9%) 5 (2.3%) 27 (12.6%) 25 (11.6%)
FH of Diabetes
Yes 94 (43.7%) 78 (36.3%)
0.004
73 (34.0%) 99 (46.1%)
0.019
113 (52.5%) 59 (27.5%)
0.91
73 (34.0%) 99 (46.1%)
0.057No 41 (19.1%) 2 (0.9%) 31 (14.4%) 12 (5.5%) 30 (14.0%) 13 (6.0%) 29 (13,4%) 14 (6.5%)
TC—Total Cholesterol, TG—Triglyceride, LDL-c—Low Density Lipoprotein Cholesterol, HDL-c—High Density Lipoprotein Cholesterol, BP—blood pressure, HTN—hypertension,
BMI—body mass index, FH—family history of diabetes.
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4. Discussion
Of the total participants, the male to female ratio was 1:1.5 (Table 1) in the present study. Diabetes
has been shown to be relatively more prevalent among females than males [20,21], and this was
reported in the current study. Majority of the respondents were ≥41 years and were married. A
similar observation was reported in a study in Cameroon by Mbanya [22], where the older age group
(≥40years) were two to three times more at risk of having diabetes, than the younger population [22].
Age has been linked to the incidence of diabetes and its associated complications, in that, older people
have increased risk due to reduced physical activity and lifestyle [23], thus the observation in the
current study. With regards to religious affiliation, Christians recorded the highest percentage, followed
by Muslims and Traditionalists.
Limited knowledge on diabetes and its associated complications somewhat influences its
occurrence [24]. Educated people have lower risk of diabetes as compared to the uneducated
or those at the lower end of the educational ladder [25]. Most of the respondents only had basic
education, while a few attained higher education, and this is consistent with a recent study among
Ghanaians in Europe and in urban Ghana, which reported decreased prevalence of diabetes with
increasing level of education [26]. A higher percentage of the participants were self-employed, with a
few into farming (Table 1). This partly concurs with a recent study in Ghana, where diabetes was most
predominant among self-employed people, with a few being farmers, albeit the percentages in the
current study were relatively higher for self-employed participants (32.6% versus 26.5%) and farmers
(21.4% versus 8.9) [27].
Diabetes mellitus is often associated with cardiovascular risk factors and subsequent prevalence
of coronary artery disease [28]. It has been reported that dyslipidemia is a major risk factor for
macrovascular complications [29]. The majority of the participants in the present study recorded high
TC and decreased HDL-c levels, while TG and LDL-c levels were normal (Table 2). This does not agree
with a similar larger study in Jordan, which reported higher TG and LDL-c levels as the most common
dyslipidaemia [30]. The disparities may be attributed to the newly diagnosed participants used in the
current study.
The high TC and low HDL-c observed in the current study were predominant in females
than in males, and in those aged >40 years (Table 2). This is consistent with a similar study by
Nakhjavani et al. [31] in Iran which reported high TC and low HDL-c levels to be significantly more
prevalent among female diabetes patients than in males, although there was no significant association
in the current study [31]. They further alluded that women with diabetes were more intensely exposed
to risk factors including higher BMI and systolic and diastolic blood pressures compared to their
male counterparts [31]. There was no significant association between both age and gender and the
individual parameters of dyslipidaemia (Table 2). Combined dyslipidaemia was further evaluated.
The prevalence rates of all combined dyslipidemia were relatively higher (Table 3) than the
individual parameters of dyslipidaemia (Table 2), with gender being significantly associated with all
combined parameters (Table 3). From the current study, the most prevalent combined dyslipidaemia
among males were high TG and decreased HDL-c levels, and were predominant among those aged
>40 years. A similar trend was observed among the female participants, thus high TG and low HDL-c
was the highest combined dyslipidemia among females. These observations partly agree with a study
by Sarfraz et al. [32] in a Pakistani population. From their results, the prevalence of dyslipidaemia was
generally increased when combinations of two parameters of dyslipidaemia were assessed. They also
identified the incidence to be predominant in the same age group (>40 years) [32]. However, high
LDL-c/low HDL-c levels were the most predominant combined dyslipidaemia in their work, which is
contrary to the leading high TG/low HDL-c combined dyslipidemia recorded in the current study [32].
The disparity may be due to differences in the study population. It has been reported that the presence
of two or more parameters of dyslipidaemia (combined dyslipidaemia) could become atherogenic,
a condition that leads to the formation of fatty deposits in arteries, and patients with diabetes are at a
higher risk [11,33,34].
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Gender may have a vital role to play in the pathophysiology of dyslipidaemia in diabetes [35],
and males may be at a higher risk for combined dyslipidaemia than females [36]. The existence of
combined dyslipidaemia in diabetes increases the risk of cardiovascular diseases [37,38]. Unlike the
results of the individual parameters of dyslipidaemia, the association between gender and combined
dyslipidaemia of high TG and low HDL-c, high TG and high LDL-c, as well as gender and high LDL-c
and low HDL-c was significant (p < 0.001 each) at 95% confidence interval. This indicates that the
incidence of combined dyslipidaemia is significantly influenced by gender [39,40]. This finding concurs
with two large studies which also reported combined dyslipidaemia to be more prevalent in males
than in females [36,41].
Studies have shown that increasing age plays a significant role in the incidence of diabetes [42] and
dyslipidaemia [43], and older people are more likely to exhibit more than one form of lipid abnormality.
The high prevalence of dyslipidaemia among respondents aged >40 years in the current study is an
indication that older age has a strong association with dyslipidaemia. This study concurs with that of
Sarfraz et al. [32], and partly agrees with that of Mbanya [22]. According to Mbanya [22], diabetes and
its associated conditions occurred most in older patients (≥56 years) [22]. This could probably be due
to lack of aerobic exercise [44]. At old age, most people do not engage in various kinds of physical
activities, such as exercise, and the higher duration of life increases the chances of elevated glucose,
dyslipidaemia, and subsequent cardiovascular diseases [45,46]. Despite the relatively high figures
suggesting some level of prevalence, the current study could not identify any significant association
between age and combined dyslipidaemia (Table 3).
Predisposing factors of dyslipidaemia include diabetes, alcoholism, hypertension, albuminuria,
and obesity [47,48]. An earlier study by Algayed et al. [49] proposed that dyslipidaemia is one
of the consequences of high BMI and vice-versa [49]. Results from the current study showed that
HDL-c level was significantly associated with BMI (Table 4), and the majority of the respondents
were overweight, with quite a number being obese (Figure 1). This finding is consistent with several
studies that reported that increasing BMI, overweight/obesity, accounts for substantial increase in the
prevalence of diabetes and subsequent lipid abnormalities [50–53]. A recent large study involving
Japanese and American subjects also concluded that higher BMI is an independent risk factor for
dyslipidaemia both in Japan and in the United States of America [54]. Another current study has also
revealed that BMI influences the occurrence of dyslipidaemia even among non-diabetics [55], which
further harnesses the BMI-dyslipidaemia association. The association of overweight and obesity to
lipid abnormalities of high TG, high LDL-c, and low HDL-c could be as result of insulin resistance,
hyperglycaemia, and reduced physical activity [56,57]. The absence of/inadequate regular physical
activity has a great influence on cardiovascular conditions due to improper circulation of blood to all
parts of the body. Thus, regular physical activities help in maintaining healthy weight, blood pressure,
and blood lipid levels [58]. Aside obesity being strongly associated with dyslipidaemia [59], it has also
been reported that elevated BMI influences other potential risk factors of dyslipidaemia, including
high blood pressure (hypertension) in both patients with diabetes [60] and without diabetes [55].
Several studies have indicated high blood pressure to be prevalent in diabetes [61–65], and this
was observed in the current study. The results showed that most of the respondents had hypertension,
followed by patients with prehypertension (Figure 1). This observation is at par with the recent
work done by Waly and Hamed [66], which found a relatively higher prevalence of hypertension
(68%) among T2DM patients [66]. Although the majority of the participants in the current study
were hypertensive, there was no significant association between blood pressure and dyslipidaemia
(Table 4). This finding is contrary to a number of cross-sectional studies, which suggested a significant
link between hypertension and lipid abnormalities [67–69]. The inconsistencies may be due to the
study setting, the newly diagnosed T2DM patients used in the current study, as well as sample size
differences. However, the relatively high prevalence of hypertension observed in the current study
may be indicative that T2DM is an independent risk factor of hypertension [70–72].
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Rother [73] proposed that there is an inheritable connection in T2DM, and hence, having relatives
with T2DM predisposes an individual to the disease [73]. More than half of the respondents in the
current study had family history of diabetes (Figure 1). These results support the relationship between
family history and the risk of T2DM, as reported by Rother [73]. Family history of diabetes was
significantly associated with TC and TG levels in the current study (Table 4). In agreement to this
report, Olokoba et al. [74] also indicated that hereditary or inheritable genetics are significant in T2DM,
and are associated with elevated cholesterol and other forms of dyslipidemia [74]. Thus, having
relatives with T2DM increases one’s likelihood of having diabetes and subsequent development of
dyslipidaemia [75–77].
Treatment and control of dyslipidemia in low income countries such as Ghana is expensive, and
the cost for treatment required to reduce further complications, especially in high-risk persons, exceeds
the resources available in such countries [78]. Lifestyle modification, which involves changes in diet
and increased physical activity/exercise, is an indispensable approach which has therefore been adopted
alongside the validated statin therapy in Ghana [79] to ensure effective channeling of the limited
resources. Prevention of dyslipidaemia is the best approach in such low-resource settings to avoid
subsequent occurrence of cardiovascular diseases (CVDs) and reduce mortality. Routine evaluation of
dyslipidaemia among high-risk individuals, such as T2DM patients is therefore recommended.
5. Conclusions
Combined dyslipidaemia is relatively high among newly diagnosed type 2 diabetes patients in
Ghana, and those >40 years are more susceptible. Gender is significantly associated with combined
dyslipidaemia in T2DM, and males may be at a higher risk than females. Overweight, obesity, and
family history of diabetes all predispose newly diagnosed T2DM patients to dyslipidaemia. The
interesting findings of the current study show that multiple dyslipidaemia is common even among
newly diagnosed T2DM patients, and this alarming situation necessitates that routine evaluation and
effective monitoring of lipid profile is ensured on the onset/diagnosis of diabetes. Thus, evaluation of
dyslipidaemia should not be overlooked in routine check-ups and management of diabetes.
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